Cardiovascular disease is the leading cause of death in patients with chronic kidney disease
(CKD). As CKD progresses, CKD-specific risk factors, such as disordered mineral …

Chronic kidney disease (CKD) is a complex condition with a prevalence of 10–15%
worldwide. An inverse-graded relationship exists between cardiovascular events and …

Cardiac remodeling occurs frequently in chronic kidney disease patients and affects quality
of life and survival. Current treatment options are highly inadequate. As kidney function …

Fibroblast growth factors (FGFs) are cell-signaling proteins with diverse functions in cell
development, repair, and metabolism. The human FGF family consists of 22 structurally …

Hyperphosphatemia or even serum phosphate levels within the “normal laboratory range”
are highly associated with increased cardiovascular disease risk and mortality in the general …

Dietary habits in the western world lead to increasing phosphate intake. Under physiological
conditions, extraosseous precipitation of phosphate with calcium is prevented by a mineral …

Fibroblast growth factor (FGF) 23 is a bone-derived phosphotropic hormone that regulates
phosphate and mineral homeostasis. Recent studies have provided evidence that a high …

Fibroblast growth factor-23 (FGF)-23 is a phosphaturic hormone involved in mineral bone
metabolism that helps control phosphate homeostasis and reduces 1, 25-dihydroxyvitamin …

The phosphaturic hormone fibroblast growth factor 23 (FGF23) is a risk marker of
cardiovascular and all-cause mortality. We therefore aimed to synthesize the evidence for …

FGF23 is a hormone secreted mainly by osteocytes and osteoblasts in bone. Its pivotal role
concerns the maintenance of mineral ion homeostasis. It has been confirmed that phosphate …